WO2024077509A1 - 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途 - Google Patents

用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途 Download PDF

Info

Publication number
WO2024077509A1
WO2024077509A1 PCT/CN2022/124795 CN2022124795W WO2024077509A1 WO 2024077509 A1 WO2024077509 A1 WO 2024077509A1 CN 2022124795 W CN2022124795 W CN 2022124795W WO 2024077509 A1 WO2024077509 A1 WO 2024077509A1
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
ifn
seq
pharmaceutical composition
poxvirus
Prior art date
Application number
PCT/CN2022/124795
Other languages
English (en)
French (fr)
Inventor
徐建青
张晓燕
丁相卿
Original Assignee
上海鑫湾生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海鑫湾生物科技有限公司 filed Critical 上海鑫湾生物科技有限公司
Priority to PCT/CN2022/124795 priority Critical patent/WO2024077509A1/zh
Publication of WO2024077509A1 publication Critical patent/WO2024077509A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma

Definitions

  • the present invention belongs to the technical field of biopharmaceuticals, and specifically relates to a pharmaceutical composition for preventing and/or treating poxvirus infection and diseases caused by poxvirus and its use.
  • Poxvirus is the largest and most complex of all viruses. When it infects humans and animals, it can cause local or systemic purulent skin lesions.
  • the Orthopoxvirus genus in poxvirus includes a variety of viruses that can cause zoonotic diseases, such as smallpox virus, monkeypox virus, cowpox virus and vaccinia virus. Orthopoxvirus is the most harmful genus among poxviruses.
  • Vaccinia virus is a large DNA virus belonging to the genus Orthopoxvirus of the Poxviridae family. There are few cases of vaccinia virus infection in humans worldwide. It was reported that in March 2017, through reports from clinicians and on-site investigations by disease control personnel, five cases of fever with unknown causes were found. All the cases were male, with symptoms of fever and lung infection, one of which developed severe pneumonia; except for one case, all had skin pustular rash. After the analysis of the infected virus genome, it was found to be highly homologous to the smallpox vaccine strain (Tiantan strain).
  • Monkeypox is caused by monkeypox virus, which is a species in the genus Orthopoxvirus of the Poxviridae family. Monkeypox is a viral zoonosis that mainly occurs in tropical rainforest areas of Central and West Africa and is occasionally exported to other areas.
  • monkeypox The typical clinical manifestations of monkeypox are fever, rash, and swollen lymph nodes, and may lead to a series of complications. Monkeypox is usually a self-limiting disease with symptoms lasting 2 to 4 weeks, and severe cases may occur. In recent years, the case fatality rate has been about 3-6%.
  • the monkeypox virus is transmitted to humans through close contact with infected people or animals, or contact with objects contaminated with the virus. Monkeypox virus is transmitted from person to person through close contact with contaminated objects such as skin lesions, body fluids, respiratory droplets and bedding.
  • monkeypox The clinical manifestations of monkeypox are similar to those of smallpox, a related orthopoxvirus infection.
  • the World Health Organization announced that smallpox had been eradicated.
  • my country announced that it would stop vaccinating against smallpox.
  • the global eradication of smallpox and the discontinuation of smallpox vaccination may have led to a decrease in human immune resistance to monkeypox virus.
  • monkeypox virus can cause serious diseases in humans and has a significant impact on human health, it is urgent to find drugs to prevent and treat monkeypox and other poxviruses.
  • Monkeypox is not as contagious as smallpox, and the disease it causes is not as serious.
  • Vaccinia virus belongs to the same family as the variola virus that causes smallpox, so vaccination with vaccines derived from vaccinia virus can prevent smallpox, monkeypox and other orthopoxvirus infections. Although vaccination is dominant in the prevention and control of poxviruses, drug treatment is particularly important for people who cannot be vaccinated (with underlying diseases, etc.) and those who are already infected. Cidofovir and Teviridavir are currently available anti-acne virus drugs on the market, but they still have problems such as low oral availability, viral resistance or nephrotoxicity.
  • Interferon can induce cells to produce antiviral immunity. It prevents or limits viral infection by interfering with viral gene transcription or viral protein translation. It is currently the most important antiviral infection and anti-tumor biological product.
  • IFN- ⁇ is the most common clinical application and is widely used in the treatment of viral diseases and tumors, such as chronic hepatitis, HPV infection, West Nile virus infection, and the treatment of skin T-cell lymphoma, renal cell carcinoma, bladder cancer, ovarian cancer, cervical cancer, basal cell carcinoma, metastatic melanoma, etc.; while IFN- ⁇ is relatively less used in viral therapy and is mainly used in the treatment of multiple sclerosis in clinical practice.
  • IFN- ⁇ is the only type II interferon and is also a signature cytokine produced by Th1 cells, CD8+T cells, ⁇ T cells, NKT cells, NK cells, dendritic cells and macrophages. It participates in the antiviral, antitumor and immune regulation of cells. IFN- ⁇ was originally recognized for its antiviral activity, and is currently widely studied in anti-tumor applications.
  • Interferon alone can cause a series of side effects, and the toxicity of IFN is dose-dependent.
  • the most common side effects include fever, chills, fatigue, headache, myalgia, arthralgia, and flu-like symptoms. It is necessary to use interferon rationally to achieve different therapeutic effects and reduce side effects. There are also few studies on the combined use of interferon.
  • IFN- ⁇ can significantly reduce the production and release of vaccinia virus (Tiantan strain).
  • IFN- ⁇ has been used clinically for the treatment of multiple sclerosis for many years, it has reliable safety.
  • IFN- ⁇ has both antiviral and immunomodulatory effects, thus suggesting that interferon ⁇ can become a new and safe treatment for the prevention and/or treatment of human poxvirus infection.
  • IFN- ⁇ can treat bacterial infections combined with chronic granulomatous diseases, rheumatoid arthritis, etc., and also has a wide range of applications and is also reliable and safe.
  • the technical problem solved by the present invention is to utilize the synergistic effect of the combined use of IFN- ⁇ and IFN- ⁇ to stimulate the host's resistance to inhibit the infection and replication of poxvirus, thereby providing an anti-poxvirus pharmaceutical composition.
  • the present invention provides the following technical solutions:
  • a pharmaceutical composition for preventing and/or treating poxvirus infection and/or diseases caused by poxvirus comprising:
  • the mass ratio of IFN- ⁇ and IFN- ⁇ , or the mass ratio of interferon- ⁇ and interferon- ⁇ expressed by the gene encoding interferon- ⁇ and the gene encoding interferon- ⁇ is 1:1 to 1:90, preferably 1:1 to 1:60, and more preferably 1:30.
  • the IFN- ⁇ is mammalian-derived IFN- ⁇ , such as human-derived or mouse-derived IFN- ⁇ .
  • nucleotide sequence of the gene encoding IFN- ⁇ is shown as SEQ ID No.1, and/or the amino acid sequence of IFN- ⁇ is shown as SEQ ID No.2.
  • the IFN- ⁇ is mammalian-derived IFN- ⁇ , such as human-derived or mouse-derived IFN- ⁇ .
  • nucleotide sequence of the gene encoding IFN- ⁇ is shown as SEQ ID No.3, and/or the amino acid sequence of IFN- ⁇ is shown as SEQ ID No.4.
  • the pharmaceutical composition comprises at least one vector, the vector comprising a nucleotide sequence such as a gene encoding IFN- ⁇ as shown in SEQ ID NO:1 and a nucleotide sequence such as a gene encoding IFN- ⁇ as shown in SEQ ID NO:3; or the pharmaceutical composition comprises at least two vectors, the vectors respectively comprising a nucleotide sequence such as a gene encoding interferon- ⁇ as shown in SEQ ID NO:1 and a nucleotide sequence such as a gene encoding interferon- ⁇ as shown in SEQ ID NO:3.
  • the vector may be selected from one or more of a plasmid vector, a poxvirus vector, an adenovirus vector, an adeno-associated virus vector, a simple virus vector, a CMV vector, a cell vector or a bacterial vector.
  • the pharmaceutical composition comprises a protein, wherein the protein comprises IFN- ⁇ with an amino acid sequence as shown in SEQ ID NO:2 and IFN- ⁇ with an amino acid sequence as shown in SEQ ID NO:4.
  • the protein may be an IFN- ⁇ protein with an amino acid sequence as shown in SEQ ID NO:2 and an IFN- ⁇ protein with an amino acid sequence as shown in SEQ ID NO:4 expressed separately; or a fusion protein, such as a fusion protein of IFN- ⁇ with an amino acid sequence as shown in SEQ ID NO:2 and an IFN- ⁇ with an amino acid sequence as shown in SEQ ID NO:4 and an Fc fragment of an antibody, or a fusion protein of IFN- ⁇ with an amino acid sequence as shown in SEQ ID NO:2 and an IFN- ⁇ with an amino acid sequence as shown in SEQ ID NO:4 and a signal peptide.
  • the protein may be modified with PEG.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the present invention provides use of the pharmaceutical composition according to the present invention in the preparation of a medicament for preventing and/or treating poxvirus infection and/or diseases caused by poxvirus.
  • the drug is an injection, an ointment or an aerosol, preferably an ointment or an aerosol, and most preferably an aerosol.
  • the poxvirus is a poxvirus of the genus Orthopoxvirus; preferably, the poxvirus is selected from one or more of vaccinia virus, monkeypox virus, molluscum contagiosum virus, yatapox virus or smallpox virus; more preferably, the poxvirus is monkeypox virus.
  • Monkeypox virus is the causative agent of monkeypox and belongs to the genus Orthopoxvirus of the family Poxviridae. It is highly related to smallpox virus and vaccinia virus in serology.
  • the disease caused by the poxvirus is selected from one or more of monkeypox, smallpox, variola, cowpox, milkman's tubercle or molluscum contagiosum.
  • the drug is administered before the poxvirus infection, administered after the poxvirus infection, or administered continuously or intermittently from before the poxvirus infection to after the infection.
  • the present invention provides a method for preventing and/or treating poxvirus infection and/or diseases caused by poxvirus, which comprises administering the pharmaceutical composition according to the present invention to a subject in need thereof.
  • the poxvirus is a poxvirus of the genus Orthopoxvirus; preferably, the poxvirus is selected from one or more of vaccinia virus, monkeypox virus, molluscum contagiosum virus, yatapox virus or smallpox virus; more preferably, the poxvirus is monkeypox virus.
  • the disease caused by the poxvirus is selected from one or more of monkeypox, smallpox, variola, cowpox milker's tubercle or molluscum contagiosum virus.
  • the pharmaceutical composition is administered before poxvirus infection, administered after poxvirus infection, or administered continuously or intermittently from before poxvirus infection to after infection.
  • the inventors have found through research that IFN- ⁇ and IFN- ⁇ can jointly inhibit the replication of vaccinia virus, showing a good antiviral synergistic effect.
  • the present invention provides a pharmaceutical composition containing IFN- ⁇ and IFN- ⁇ and a new use thereof based on the inhibitory function of IFN- ⁇ and IFN- ⁇ on the replication of vaccinia virus.
  • the beneficial effect of the present invention is that compared with the prior art, the present invention has discovered a pharmaceutical composition of IFN- ⁇ and IFN- ⁇ and a new use thereof, that is, the combination of IFN- ⁇ and IFN- ⁇ can significantly inhibit the replication of vaccinia virus, which has important clinical application value for preventing and treating new and sudden diseases caused by poxviruses such as vaccinia virus and monkeypox virus.
  • FIG1 shows the effects of IFN- ⁇ , ⁇ 1, ⁇ 2, ⁇ and ⁇ on the status of human thymidine kinase-deficient cell line TK143- cells at concentrations of 1 ng/mL, 27 ng/mL and 81 ng/mL.
  • Figure 2 shows the inhibitory effects of IFN- ⁇ , ⁇ 1, ⁇ 2, ⁇ and ⁇ on vaccinia virus (Tiantan strain) replication in the human thymidine kinase-deficient cell line TK143- at concentrations of 1 ng/mL, 3 ng/mL, 9 ng/mL, 27 ng/mL and 81 ng/mL, respectively.
  • FIG3 shows the effects of IFN- ⁇ alone, IFN- ⁇ alone, and the combination of IFN- ⁇ and IFN- ⁇ on the inhibition of vaccinia virus replication by T cells at effector-target ratios of 0, 1:1, 1:2, 1:4, and 1:8.
  • the experimental methods used in the following examples are conventional methods unless otherwise specified.
  • the cells, culture media, kits, etc. used in the following examples are commercially available products unless otherwise specified.
  • Example 1 Comparison of the inhibitory effects of IFN- ⁇ , ⁇ 1, ⁇ 2, ⁇ , and ⁇ on vaccinia virus infection
  • TK143 cells purchased from ATCC
  • TK143 cells purchased from ATCC
  • the cell density should reach 90% of the bottom area of the 24-well plate when used;
  • IFN- ⁇ , ⁇ 1, ⁇ 2, ⁇ and ⁇ at concentrations of 1 ng/mL, 3 ng/mL, 9 ng/mL, 27 ng/mL and 81 ng/mL, respectively (IFN- ⁇ , ⁇ 1, ⁇ 2, ⁇ were purchased from Beijing Sino Biological Technology Co., Ltd., and IFN- ⁇ was purchased from Suzhou Nearshore Protein Technology Co., Ltd.) for pre-stimulation.
  • IFN- ⁇ had a significant inhibitory effect on the replication of vaccinia virus at a concentration of 1 ng/mL, and the number of plaques decreased from 34 plaques in the control group without interferon to 8, and the plaque size and fluorescence brightness also decreased significantly.
  • the inhibitory effect on vaccinia virus increased with the increase of IFN- ⁇ concentration (see Figure 2 and Table 1), and it had no obvious damage to cells (see Figure 1).
  • Other factors had no significant inhibitory effect on vaccinia virus replication at the same concentration.
  • Example 2 IFN- ⁇ and IFN- ⁇ proteins have a synergistic effect on the inhibition of vaccinia virus infection
  • TK143 cells were plated in a 24-well plate, with 1E5 cells per well. The cell density should reach 90% of the bottom area of the 24-well plate when used;
  • the effector-target ratio the ratio of effector cells (T cells, important lymphocytes existing in the human body) to target cells (cells infected with vaccinia virus, i.e., TK143 - cell line)
  • the effector-target ratio was 1:4, the number of plaques decreased from 16 plaques in the untreated control group to 3 plaques, and the plaque size and fluorescence brightness also decreased significantly; in contrast, there were 40 plaques in the IFN- ⁇ alone treatment group, 48 plaques in the IFN- ⁇ alone treatment group, 7 plaques in the IFN- ⁇ alone plus T cell group, and 20 plaques in the IFN- ⁇ alone plus T cell group.
  • the effector-target ratio was 1:8, the number of plaques in the IFN- ⁇ +IFN- ⁇ group was reduced from 30 plaques in the untreated control group to 10; in contrast, there were 14 plaques in the IFN- ⁇ plus T cell group and 34 plaques in the IFN- ⁇ plus T cell group (see Figure 3 and Table 2). It can be seen that the combination of IFN- ⁇ and IFN- ⁇ has a significant synergistic effect and can significantly enhance the ability to resist vaccinia virus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明提供了一种用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途。该药物组合包含：（1）干扰素-β和干扰素-γ；或者（2）干扰素-β的编码基因、干扰素-γ的编码基因和载体。该药物组合物能够抑制痘苗病毒的复制，可用于预防与治疗痘苗病毒和猴痘病毒等痘病毒导致的新发、突发疾病。

Description

用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途 技术领域
本发明属于生物制药技术领域，具体涉及一种用于预防和/或治疗痘病毒感染及其引发的疾病的药物组合物及其用途。
背景技术
痘病毒是所有病毒中最大、最复杂的病毒，其感染人和动物后会造成局部或全身化脓性皮肤损害。痘病毒中的正痘病毒属包括多种能够引起人畜共患病的病毒种类，如天花病毒、猴痘病毒、牛痘病毒和痘苗病毒等，正痘病毒是痘病毒中危害最为严重的一个属。
痘苗病毒是一种大DNA病毒，属痘病毒科正痘病毒属，在世界范围内鲜有痘苗病毒感染人的病例，有报道的是2017年3月通过临床医生的报告和疾控人员的现场调查，先后发现5例有流行病学关联原因不明的发热病例。病例均为男性，有发热、肺部感染症状，其中一例发展为重症肺炎；除一例外，均有皮肤脓疱疹。后经过感染的病毒基因组分析，其与天花疫苗株(天坛株)高度同源。
2017年以来，尼日利亚爆发了较大规模的猴痘疫情，共报告疑似病例500余例，确诊病例200余例，病死率达约3％，目前仍在不断新增。2018年至2022年，还发生过多例从尼日利亚到其他国家的游客感染猴痘的病例，涉及以色列、英国、新加坡、美国等。猴痘是由猴痘病毒引起的，该病毒是痘病毒科正痘病毒属中的一种。猴痘是一种病毒性人畜共患病，主要发生在中非和西非的热带雨林地区，偶尔输出到其它地区。猴痘在临床上的典型表现为发热、皮疹和淋巴结肿大，并可能导致一系列并发症。猴痘通常是一种自限性疾病，症状持续2至4周，可能会发生严重病例。近年来，病死率约为3-6％。猴痘病毒通过与受感染的人或动物密切接触，或与被病毒污染的物体接触而传播给人类。猴痘病毒通过密切接触皮肤损伤、体液、呼吸道飞沫和被褥等受污染物体在人与人之间传播。
猴痘的临床表现类似于天花，后者是一种相关的正痘病毒感染。1980年5月8日，世界卫生组织宣布天花被彻底根除。1981年，我国宣布停止接 种天花疫苗。全球天花的消灭以及天花的疫苗接种终断可能导致人对猴痘病毒的免疫抵抗力降低。由于猴痘病毒能够引起人类严重疾病，对人类健康造成重大影响，所以寻找预防和治疗猴痘及其他痘病毒的药物刻不容缓。猴痘的传染性不如天花，引起的疾病也没有那么严重，为治疗天花而开发的一种抗病毒药物也已获得许可用于治疗猴痘。痘苗病毒与导致天花的天花病毒属于同一个科，因此接种源自痘苗病毒的疫苗可以预防天花、猴痘及其他正痘病毒感染。虽然疫苗接种在预防和控制痘病毒方面占主导地位，但对于不能接种疫苗(有基础病等)和已感染的人群来说药物治疗显得尤为重要。西多福韦和替韦立马是目前已上市的抗痘病毒药物，但它们依然存在着口服利用度低、病毒耐药性或肾毒性等问题。
干扰素(Interferon，IFN)能诱导细胞产生抗病毒免疫，其通过干扰病毒基因转录或病毒蛋白的翻译从而阻止或限制病毒感染，是目前最主要的抗病毒感染和抗肿瘤生物制品。其中，IFN-α的临床应用最为普遍，被广泛应用于病毒性疾病治疗和肿瘤治疗，例如慢性肝炎、HPV感染、西尼罗河病毒感染等和皮肤T-细胞淋巴瘤、肾细胞癌、膀胱癌、卵巢癌、宫颈癌、基底细胞癌、转移性黑色素瘤等的治疗；而IFN-β对于病毒治疗的应用相对较少，临床上主要用于多发性硬化症的治疗。近来有实验发现相对于IFN-α，痘病毒对于IFN-β的刺激更为敏感。IFN-γ是唯一的II型干扰素，也是Th1细胞、CD8+T细胞、γδT细胞、NKT细胞、NK细胞、树突状细胞和巨噬细胞产生的标志性细胞因子，它参与细胞的抗病毒、抗肿瘤和免疫调控作用。IFN-γ最初是由于其抗病毒活性而被认识，目前IFN-γ在抗肿瘤的应用中有广泛的研究。
干扰素单独用药会有一系列的副作用，且IFN的相关毒性为剂量依赖性，最常见的副作用包括发热、寒战、乏力、头痛、肌痛、关节痛和流感样。有必要对干扰素进行合理的应用以实现不一样的治疗效果，同时减弱副作用，对于干扰素联用的应用研究也很少。
发明内容
针对现有技术的不足，本申请的发明人在实验中发现采用人IFN-β和IFN-γ治疗可以显著减少痘苗病毒(天坛株)的产生、释放。鉴于IFN-β在临床上用于多发性硬化症的治疗已有多年，具有可靠的安全性。另外，与单 纯抗病毒的药物相比，IFN-β同时具有抗病毒和免疫调节的双重作用，因此提示干扰素β可以成为预防和/或治疗人类痘病毒感染的一种新的安全的治疗手段。而IFN-γ可治疗慢性肉芽肿性疾病合并的细菌感染、类风湿关节炎等，也具有广泛的应用，同样具有可靠的安全性。
本发明所解决的技术问题是：利用IFN-β和IFN-γ联用产生的协同效应激发宿主的抵抗力来抑制痘病毒的感染和复制，从而提供一种抗痘病毒药物组合物。
为了解决上述技术问题，本发明提供了以下技术方案：
一种用于预防和/或治疗痘病毒感染和/或其引发的疾病的药物组合物，其包含：
(1)干扰素-β和干扰素-γ；或者
(2)干扰素-β的编码基因、干扰素-γ的编码基因和载体。
根据本发明的一些实施方案，IFN-β和IFN-γ的质量比、或干扰素-β的编码基因和干扰素-γ的编码基因表达的干扰素-β和干扰素-γ的质量比为1：1至1：90，优选为1：1至1：60，更优选为1：30。
根据本发明的一些实施方案，IFN-β为哺乳动物来源的IFN-β，例如人源或鼠源IFN-β。
根据本发明的一些优选实施方案，IFN-β的编码基因的核苷酸序列如SEQ ID No.1所示，和/或IFN-β的氨基酸序列如SEQ ID No.2所示。
根据本发明的一些实施方案，IFN-γ为哺乳动物来源的IFN-γ，例如人源或鼠源IFN-γ。
根据本发明的一些优选实施方案，IFN-γ的编码基因的核苷酸序列如SEQ ID No.3所示，和/或IFN-γ的氨基酸序列如SEQ ID No.4所示。
根据本发明的一些实施方案，药物组合物包含至少一种载体，所述载体包含核苷酸序列如SEQ ID NO:1所示的IFN-β的编码基因和核苷酸序列如SEQ ID NO:3所示的IFN-γ的编码基因；或者所述药物组合物包含至少两种载体，所述载体分别包含核苷酸序列如SEQ ID NO:1所示的干扰素-β的编码基因和核苷酸序列如SEQ ID NO:3所示的干扰素-γ的编码基因。所述载体可以选自质粒载体、痘病毒载体、腺病毒载体、腺相关病毒载体、单纯病毒载体、CMV载体、细胞载体或细菌载体中的一种或多种。
根据本发明的一些实施方案，药物组合物包含蛋白，所述蛋白包含氨 基酸序列如SEQ ID NO:2所示的IFN-β和氨基酸序列如SEQ ID NO:4所示的IFN-γ。所述蛋白可以为单独表达的氨基酸序列如SEQ ID NO:2所示的IFN-β蛋白和氨基酸序列如SEQ ID NO:4所示的IFN-γ蛋白；或者为融合蛋白，例如氨基酸序列如SEQ ID NO:2所示的IFN-β和氨基酸序列如SEQ ID NO:4所示的IFN-γ与抗体的Fc片段的融合蛋白，或氨基酸序列如SEQ ID NO:2所示的IFN-β和氨基酸序列如SEQ ID NO:4所示的IFN-γ与信号肽的融合蛋白。此外，所述蛋白还可以用PEG修饰。
根据本发明的一些实施方案，药物组合物还包括药学上可接受的辅料。
另一方面，本发明提供了根据本发明的药物组合物在用于制备预防和/或治疗痘病毒感染和/或其引发的疾病的药物中的用途。
根据本发明的一些实施方案，药物为注射剂、软膏剂或气雾剂，优选为软膏剂或气雾剂，最优为气雾剂。
根据本发明的一些实施方案，痘病毒为正痘病毒属痘病毒；优选地，痘病毒选自痘苗病毒、猴痘病毒、传染性软疣病毒、yata痘病毒或天花病毒中的一种或多种；更优选地，痘病毒为猴痘病毒。猴痘病毒是猴痘的病原体，属痘病毒科正痘病毒属，其在血清学上与天花病毒、痘苗病毒高度相关。
根据本发明的一些实施方案，痘病毒引发的疾病选自猴痘、天花、类天花、牛痘、挤奶员结节或传染性软疣中的一种或多种。
根据本发明的一些实施方案，药物在痘病毒感染前给药，在痘病毒感染后给药，或自痘病毒感染前至感染后连续或间隔给药。
相应地，本发明提供了一种用于预防和/或治疗痘病毒感染和/或其引发的疾病的方法，其包括向有其需要的对象给予根据本发明的药物组合物。
根据本发明的一些实施方案，痘病毒为正痘病毒属痘病毒；优选地，痘病毒选自痘苗病毒、猴痘病毒、传染性软疣病毒、yata痘病毒或天花病毒中的一种或多种；更优选地，痘病毒为猴痘病毒。
根据本发明的一些实施方案，痘病毒引发的疾病选自猴痘、天花、类天花、牛痘挤奶员结节或传染性软疣病毒中的一种或多种。
根据本发明的一些实施方案，药物组合物在痘病毒感染前给药，在痘 病毒感染后给药，或自痘病毒感染前至感染后连续或间隔给药。
本发明人经研究发现，IFN-β和IFN-γ可联合抑制痘苗病毒的复制，显示出很好的抗病毒协同效果。本发明基于IFN-β和IFN-γ对痘苗病毒复制的抑制功能提供了包含IFN-β和IFN-γ的药物组合物及其新用途。
本发明的有益效果在于：与现有技术相比，本发明发现了IFN-β和IFN-γ的药物组合物及其新用途，即IFN-β和IFN-γ联用能够显著地抑制痘苗病毒的复制，这对于预防与治疗痘苗病毒和猴痘病毒等痘病毒导致的新发、突发疾病有重要的临床应用价值。
应理解，在本发明范围内，本发明的上述各项技术特征和在下文(如实施例)中具体描述的各项技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅限制，在此不再一一赘述。
附图的简要说明
以下，结合附图来详细说明本发明的实施方案，其中：
图1显示了在1ng/mL、27ng/mL和81ng/mL浓度下，IFN-β、α1、α2、γ和κ对人胸腺激酶缺陷性细胞系TK143 -细胞的状态的影响。
图2显示了在1ng/mL、3ng/mL、9ng/mL、27ng/mL和81ng/mL浓度下，IFN-β、α1、α2、γ和κ分别在人胸腺激酶缺陷性细胞系TK143 -中对痘苗病毒(天坛株)复制的抑制作用。
图3显示了在效靶比为0、1：1、1：2、1：4和1：8的情况下，单独的IFN-β、单独的IFN-γ以及IFN-β和IFN-γ联合通过T细胞抑制痘苗病毒复制的作用。
实施发明的最佳方式
下面结合具体实施方式对本发明进行进一步的详细描述，给出的实施例仅为了阐明本发明，而不是为了限制本发明的范围。
下述实施例中所用的实验方法，如无特殊说明，均为常规方法。下述实施例中所用的细胞、培养基、试剂盒等，如无特殊说明，均为市售产品。
实施例1：IFN-β、α1、α2、γ、κ几种因子对痘苗病毒感染的抑制作用的比较
1.TK143 -细胞的准备：在24孔板中铺TK143 -细胞(购自ATCC)，每孔1E5个细胞，使用时细胞密度达到24孔板底面积的90％；
2.弃掉24孔板中的完全培养基，换上新的完全培养基，分别加入1ng/mL、3ng/mL、9ng/mL、27ng/mL和81ng/mL浓度的IFN-β、α1、α2、γ和κ(IFN-β、α1、α2、γ购自北京义翘神州科技股份有限公司，IFN-κ购自苏州近岸蛋白质科技股份有限公司)进行预刺激。
3. 24h后弃掉24孔板中的完全培养基，换上新的D2培养基(含2％FBS的完全培养基)，并分别加入与步骤2中相同浓度的因子和痘苗病毒稀释液(MOI＝0.02)，放入培养箱培养。
4. 24h后观察几种不同IFN对细胞状态以及形成病毒噬斑数量和大小的影响。
结果显示，相对于其他四种IFN因子，IFN-β在1ng/mL的浓度下对痘苗病毒的复制有明显的抑制作用，噬斑数由未加干扰素的对照组的34个噬斑降低到了8个，且噬斑大小和荧光亮度也显著降低，并且随着IFN-β浓度的增加对痘苗病毒的抑制作用增强(参见图2和表1)，而且其对细胞无明显损伤(参见图1)。其他因子在相同浓度下对痘苗病毒复制没有明显的抑制作用。
表1几种IFN对痘苗病毒感染的抑制作用的比较
Figure PCTCN2022124795-appb-000001
注：加号数量越多说明则噬斑越大，荧光越强。
实施例2：IFN-β和IFN-γ蛋白对痘苗病毒感染的抑制有协同效应
1.TK143 -细胞的准备：在24孔板中铺TK143 -细胞，每孔1E5个细胞，使用时细胞密度达到24孔板底面积的90％；
2.弃掉24孔板中的完全培养基，换上新的完全培养基，分成8组，分别是空白对照组、T细胞处理组、IFN-β单独处理组、IFN-β加T细胞处理组，IFN-γ单独处理组、IFN-γ加T细胞处理组、IFN-β联合IFN-γ处理组、IFN-β联合IFN-γ加T细胞处理组，其中加入的IFN-β的工作浓度是0.3ng/mL，IFN-γ的工作浓度是9ng/mL。
3. 24h后弃掉24孔板中的完全培养基，换上新的D2培养基(含2％FBS的完全培养基)，并分别加入与步骤2中相同浓度的因子和痘苗病毒稀释液(MOI＝0.02)，放入培养箱培养。
4. 24h后观察不同组感染痘苗病毒后对细胞状态以及形成病毒噬斑数量和大小的影响。
结果显示，单独T细胞组对病毒复制有明显的抑制，且随着T细胞数目的增多，对痘苗病毒的抑制越发显著；但当效靶比(是指效应细胞(T细胞，人体中自身存在的重要的淋巴细胞)与靶细胞(痘苗病毒感染的细胞，即TK143 -细胞系)的比例)是1：4或者1：8时，抑制病毒复制的效果下降，这时通过IFN-β和IFN-γ处理会明显增加对痘毒复制的抑制。在效靶比为1：4时，噬斑数由未处理对照组的16个噬斑降低到了3个，且噬斑大小和荧光亮度也显著降低；相比之下，IFN-β单独处理组有40个，单独IFN-γ处理组有48个，单独IFN-β加T细胞组的7个以及单独IFN-γ加T细胞组有20个。在效靶比为1：8时，IFN-β+IFN-γ的噬斑数由未处理对照组的30个噬斑降低到了10个；相比之下，IFN-β加T细胞组有14个，IFN-γ加T细胞组有34个(参见图3和表2)。由此可知，IFN-β和IFN-γ联合具有明显的协同效应，可显著增强抗痘苗病毒的能力。
对比图2(表1)与图3(表2)的结果可知，在单独使用IFN-γ的情况下，在工作浓度为9ng/mL时没有抑制痘苗病毒的活性，而单独使用工作浓度为1ng/mL的IFN-β时的抑制效果与0.3ng/mL的IFN-β联合9ng/mL的IFN-γ的抑制痘苗病毒效果是相当的，即IFN-β的使用剂量可以降低3倍。总的来说，本发明提供的药物组合物在极大降低干扰素使用剂量的情况下同样可以达到有效的治疗目的，这对于降低干扰素的副反应有重要作用。
表2 IFN-β和IFN-γ对痘苗病毒感染的抑制
Figure PCTCN2022124795-appb-000002
注：
IFN-β：0.3ng/ml
IFN-γ：9ng/ml
TK143 -细胞：1E5
加号数量越多说明则噬斑越大，荧光越强。
以上显示和描述了本发明的基本原理、主要特征和优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中的描述只是说明本发明的原理，在不脱离本发明的精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的发明范围内。本发明要求保护的范围由所附的权利要求书及其等同方案界定。

Claims (10)

  1. 一种用于预防和/或治疗痘病毒感染和/或其引发的疾病的药物组合物，其包含：
    (1)干扰素-β和干扰素-γ；或者
    (2)干扰素-β的编码基因、干扰素-γ的编码基因和载体。
  2. 根据权利要求1所述的药物组合物，其中，所述干扰素-β和干扰素-γ的质量比、或所述干扰素-β的编码基因和干扰素-γ的编码基因表达的干扰素-β和干扰素-γ的质量比为1：1至1：90，优选为1：1至1：60，更优选为1：30。
  3. 根据权利要求1或2所述的药物组合物，其中，所述干扰素-β为哺乳动物来源的干扰素-β，例如人源或鼠源干扰素-β；
    优选地，所述干扰素-β的编码基因的核苷酸序列如SEQ ID No.1所示，和/或IFN-β的氨基酸序列如SEQ ID No.2所示；
    优选地，所述干扰素-γ为哺乳动物来源的干扰素-γ，例如人源或鼠源干扰素-γ；
    优选地，所述干扰素-γ的编码基因的核苷酸序列如SEQ ID No.3所示，和/或IFN-γ的氨基酸序列如SEQ ID No.4所示。
  4. 根据权利要求1至3中任一项所述的药物组合物，其中，所述药物组合物包含至少一种载体，所述载体包含核苷酸序列如SEQ ID NO:1所示的干扰素-β的编码基因和核苷酸序列如SEQ ID NO:3所示的干扰素-γ的编码基因；或者所述药物组合物包含两种载体，所述载体分别包含核苷酸序列如SEQ ID NO:1所示的干扰素-β的编码基因和核苷酸序列如SEQ ID NO:3所示的干扰素-γ的编码基因；
    优选地，所述载体选自质粒载体、痘病毒载体、腺病毒载体、腺相关病毒载体、单纯病毒载体、CMV载体、细胞载体或细菌载体中的一种或多种。
  5. 根据权利要求1至3中任一项所述的药物组合物，其中，所述药物组合物包含蛋白，所述蛋白包含氨基酸序列如SEQ ID NO:2所示的IFN-β和氨基酸序列如SEQ ID NO:4所示的IFN-γ；
    优选地，所述蛋白为单独表达的氨基酸序列如SEQ ID NO:2所示的IFN-β蛋白和氨基酸序列如SEQ ID NO:4所示的IFN-γ蛋白；或者为融合蛋白，例如氨基酸序列如SEQ ID NO:2所示的IFN-β和氨基酸序列如SEQ ID NO:4所示的IFN-γ与抗体的Fc片段的融合蛋白，或氨基酸序列如SEQ ID NO:2所示的IFN-β和氨基酸序列如SEQ ID NO:4所示的IFN-γ与信号肽的融合蛋白；
    优选地，所述蛋白用PEG修饰。
  6. 根据权利要求1至5中任一项所述的药物组合物，其还包括药学上可接受的辅料。
  7. 根据权利要求1至5中任一项所述的药物组合物在用于制备预防和/或治疗痘病毒感染和/或其引发的疾病的药物中的用途；
    优选地，所述药物为注射剂、软膏剂或气雾剂，优选为软膏剂或气雾剂，最优为气雾剂。
  8. 根据权利要求7所述的用途，其中，所述痘病毒为正痘病毒属痘病毒；优选地，所述痘病毒选自痘苗病毒、猴痘病毒、传染性软疣病毒、yata痘病毒或天花病毒中的一种或多种；更优选地，所述痘病毒为猴痘病毒。
  9. 根据权利要求7或8所述的用途，其中，所述痘病毒引发的疾病选自猴痘、天花、类天花、牛痘、挤奶员结节或传染性软疣中的一种或多种。
  10. 根据权利要求7至9中任一项所述的用途，其中，所述药物在痘病毒感染前给药，在痘病毒感染后给药，或自痘病毒感染前至感染后连续或间隔给药。
PCT/CN2022/124795 2022-10-12 2022-10-12 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途 WO2024077509A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/124795 WO2024077509A1 (zh) 2022-10-12 2022-10-12 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/124795 WO2024077509A1 (zh) 2022-10-12 2022-10-12 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途

Publications (1)

Publication Number Publication Date
WO2024077509A1 true WO2024077509A1 (zh) 2024-04-18

Family

ID=90668598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/124795 WO2024077509A1 (zh) 2022-10-12 2022-10-12 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途

Country Status (1)

Country Link
WO (1) WO2024077509A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553807A (zh) * 2001-09-11 2004-12-08 �Ƹ��� 含有治疗性蛋白混合物的组合物及其生产方法
CN112980883A (zh) * 2021-03-03 2021-06-18 广州达博生物制品有限公司 一种人γ-干扰素病毒载体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553807A (zh) * 2001-09-11 2004-12-08 �Ƹ��� 含有治疗性蛋白混合物的组合物及其生产方法
CN112980883A (zh) * 2021-03-03 2021-06-18 广州达博生物制品有限公司 一种人γ-干扰素病毒载体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHN GOULDING: "CD8 T Cells Use IFN-γ To Protect against the Lethal Effects of a Respiratory Poxvirus Infection", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 192, no. 11, 1 June 2014 (2014-06-01), US , pages 5415 - 5425, XP093158906, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1400256 *
SARA C JOHNSTON ET AL.: "In vitro inhibition of monkeypox virus production and spread by Interferon-β", VIROL J., vol. 9, 6 January 2012 (2012-01-06), XP021131567, ISSN: 1743-422X, DOI: 10.1186/1743-422X-9-5 *
SUN, YAJIE; WANG, JINGYAN: "Research Progress of Anti-poxvirus Drugs", JOURNAL OF INTERNATIONAL PHARMACEUTICAL RESEARCH, JUNSHI YIXUE KEXUEYUAN * DUWU YAOWU JIANJIUSUO, CN, vol. 33, no. 1, 28 February 2006 (2006-02-28), CN , pages 37 - 41, XP009555288, ISSN: 1674-0440, DOI: 10.13220/j.cnki.jipr.2006.01.013 *

Similar Documents

Publication Publication Date Title
KR20080084528A (ko) 종양살상형 백시니아 바이러스 암 치료
JP5209462B2 (ja) コンセンサスインターフェロンの使用方法
WO2021161043A1 (en) Prevention and treatment of infections including those caused by coronavirus
WO2019062233A1 (zh) 包含分离的重组溶瘤痘病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
CN108261426B (zh) 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
CN111658779A (zh) 治疗新型冠状病毒肺炎的联合用药物
JP5037775B2 (ja) 抗ウイルス薬および癌に対する医薬の製造のためのパラポックスウイルスｏｖｉｓの使用
Lu et al. Mpox (formerly monkeypox): pathogenesis, prevention, and treatment
WO2003078640A2 (en) Recombinant drug-sensitive vaccinia virus as smallpox vaccine
CN101312737B (zh) 副痘病毒与传统细胞毒性化疗剂联合作为治疗癌症的生化治疗
WO2024077509A1 (zh) 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途
CN116459295B (zh) 一种肺炎清化方及其应用
CN105597092A (zh) 含有白介素15的防治hpv感染的疫苗喷雾剂
WO2020108427A1 (zh) 一种新型干扰素α及其制备方法、组合物和用途
Ohe et al. Sensitivity of FCV to recombinant feline interferon (rFeIFN)
CN117860870A (zh) 用于预防和治疗痘病毒感染及其引发的疾病的药物组合物及其用途
JP2000007578A (ja) Ｃ型肝炎ウイルスの陰性化のための投薬システム
CN114246847A (zh) 查尔酮类化合物在治疗冠状病毒感染中的应用
Schiltknecht et al. Influenza Virus‐Specific T Cells Fail to Reduce Lung Virus Titres in Cyclosporin‐Treated, Infected Mice
JP2012121902A (ja) 抗ウイルス薬および癌に対する医薬を製造するためのパラポックスウイルスｏｖｉｓ株の使用
CN110876759A (zh) M基因突变的水疱型口炎病毒在抗肿瘤药物中的应用
US20230088483A1 (en) Use of recombinant cytokine gene derived protein or fragment thereof
CN111450232B (zh) 一种融合蛋白在制备治疗丙型肝炎药物中的应用
Wirth et al. Immunological elimination of infected cells as the candidate mechanism for tumor protection in polyomavirus-infected mice
Nguyen et al. Oncolytic Virus–an Effective Targeting Therapy for Cancer Treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22961701

Country of ref document: EP

Kind code of ref document: A1